Core Viewpoint - The company Aiwei Electric is facing significant challenges in its IPO process, including unresolved equity arbitration, declining product prices, and a complex financial situation, despite showing impressive growth in revenue and net profit over recent years [1][3][5]. Group 1: Equity Structure and Legal Issues - The company has a complicated equity structure involving shareholding proxies, which has led to an ongoing arbitration case regarding the ownership of shares held by proxy since its establishment in 2017 [3][5]. - The unresolved arbitration and litigation present a major uncertainty for the company's IPO, contrasting sharply with the strict requirements for clear equity structures set by the Shenzhen Stock Exchange [5]. Group 2: Business Dependency and Pricing Concerns - Aiwei Electric relies almost entirely on a single product, the thermal management high-voltage controller, which accounts for 99.86% of its revenue [6]. - The sales price of this product has been declining, with a cumulative decrease of 18.3% from 2022 to 2024, which is compressing the company's profit margins [6][8]. - The company's production and sales rate dropped to 88.09% in 2024, leading to a significant increase in inventory, which reached a book value of 103.3 million yuan, a 69.37% increase from the previous year [6][8]. Group 3: Financial Operations and Cash Flow - The company has distributed a total of 58.88 million yuan in cash dividends prior to its IPO application, raising questions about its financial strategy, especially as it plans to raise 70 million yuan for working capital despite having a cash balance of 412 million yuan at the end of 2024 [9][11]. - The company's asset-liability ratio has significantly improved, dropping to 29.62% by the end of 2024, compared to 76.25% in 2022, indicating a healthier financial position [10][12]. Group 4: Research and Development Concerns - There has been a dramatic increase in R&D expenses and personnel, with R&D costs rising from 11.51 million yuan in 2022 to 47.06 million yuan in 2024, raising concerns about the sustainability and authenticity of these expenditures [13][14]. - The rapid expansion of the R&D team, which grew from 30 to 138 members in two years, has led to skepticism regarding the effectiveness and management of the R&D budget [16]. Group 5: Capital Structure and Investment Risks - The company plans to raise 930 million yuan in its IPO, which exceeds its total assets of 817 million yuan as of the end of 2024, leading to questions about the rationale behind such a large fundraising target [20][21]. - The involvement of external investors like Xiaomi and NIO prior to the IPO, along with special rights clauses that could affect control stability, adds another layer of complexity to the company's capital structure [17][19]. Group 6: Market Position and Competitive Landscape - The company’s largest customer, Suzhou Zhongcheng New Energy, contributed 1.93 billion yuan in sales, accounting for 43.72% of Aiwei Electric's revenue, highlighting the risks associated with customer concentration [23]. - The ongoing price war in the electric vehicle sector is impacting the supply chain, with the company facing increased inventory levels that could pose significant risks to its operations [23].

Core Viewpoint - Saintong Special Medical, a supplier of medical food, is seeking to list on the Hong Kong Stock Exchange, showcasing strong revenue growth but facing challenges due to high dependency on a single product line and low R&D investment [2][4][15]. Financial Performance - Saintong Special Medical has maintained a high gross margin of 71% over the years, with projected revenues increasing from RMB 4.91 billion in 2022 to RMB 8.34 billion in 2024, representing a 1.7 times growth over three years [8][9]. - The net profit margin is relatively low at 11.3%, with net profits of RMB 0.84 billion, RMB 1.7 billion, and RMB 0.94 billion for the years 2022 to 2024 respectively [16][15]. Revenue Structure - Over 90% of the company's revenue comes from allergy prevention products, with this segment's contribution increasing from 85.5% in 2022 to 90.3% in 2024 [8][9]. - Other product lines, such as premature infant products and lactose-free products, contribute less than 10% to total revenue [9]. R&D and Marketing Expenditure - The company has allocated less than 2% of its revenue to R&D, with expenditures of RMB 6.51 million, RMB 10.81 million, and RMB 13.30 million from 2022 to 2024, while marketing expenses have been significantly higher [13][15]. - Marketing expenses accounted for approximately 39% to 41% of total revenue during the same period [13]. Market Position - Saintong Special Medical holds a 9.5% market share in the domestic infant medical food market, ranking third, while its overall market share in the medical food sector is only 6.3% [14]. - The company faces intense competition from both domestic and international firms, with the top three competitors holding a combined market share of nearly 70% [14]. Inventory Management - The inventory turnover days have increased significantly, from 54 days in 2022 to 155 days in 2024, indicating potential inefficiencies in inventory management [14]. Dividend Policy - The company has been generous with dividends, distributing a total of RMB 4.67 billion from 2022 to March 2023, despite low R&D investment [15][17]. Listing Pressure - Saintong Special Medical is under pressure to meet certain conditions related to its IPO, including the potential restoration of special rights for investors if the listing is not successful by the end of 2026 [18].